Navigation Links
Graham Cooper Appointed Chief Financial Officer of Receptos

SAN DIEGO, Feb. 14, 2013 /PRNewswire/ -- Receptos, Inc. announced today that Graham Cooper has been appointed Chief Financial Officer. Mr. Cooper joins the company after serving as Chief Financial Officer of Geron Corporation and Orexigen Therapeutics, Inc.

"Graham brings to Receptos tremendous strategic insight and financial experience, including Orexigen's successful initial public offering," said Faheem Hasnain , President and Chief Executive Officer of Receptos. "Graham will play a key leadership role as we capitalize Receptos to execute on our clinical development strategy. He joins us at a particularly exciting time, having initiated the Phase 2 portion of our randomized Phase 2/3 study for RPC1063, which has the potential to be the next S1P1R modulator to market in relapsing multiple sclerosis."

Added Mr. Cooper, "I see a great deal of promise in Receptos' pipeline of therapeutics as well as its skilled leadership team. Receptos is a fast-moving company with a history of strong execution, and I look forward to our evolution into a late-stage clinical development organization."

Cooper joins Receptos from Geron, where he served as EVP-Finance and Chief Financial Officer. In this capacity, he led investor relations and financial activities and served on the Executive Management Committee that oversaw clinical, research, regulatory and financial activities. Prior to Geron, he served as SVP-Finance and Chief Financial Officer of Orexigen from 2006 to 2012. During his tenure, Orexigen raised over $300 million in public and private equity, including $80 million through an initial public offering. Earlier in his career, he served as Director of healthcare banking for Deutsche Bank and as a Senior Accountant for Deloitte & Touche, where he earned his CPA. He received a Master's degree in Business Administration from the Graduate School of Business at Stanford University and a Bachelor's degree in Economics from the University of California, Berkeley.

About Receptos
Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The company's lead program, RPC1063, is a potential best-in-class sphingosine 1-phosphate 1 receptor (S1P1R) small molecule modulator for immune indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). Receptos is currently enrolling patients into the randomized Phase 2 portion of a Phase 2/3 study examining the efficacy of RPC1063 in RMS and a randomized Phase 2 study examining the efficacy of RPC1063 in ulcerative colitis (UC). Receptos has established expertise in high resolution protein crystal structure determination, biology and drug discovery for G-protein-coupled receptors (GPCRs). This expertise has formed the basis of collaborations with Eli Lilly and Ono Pharmaceutical and a partnership with Janssen Pharmaceuticals, Inc. For more information visit

Media and Investor Contacts:
Russo Partners
Ian Stone or David Schull (media)
(619) 308-6541 or (212) 845-4271

SOURCE Receptos, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
2. Dehaier Medical Announces Strategic Mutual Cooperation Agreement with HEYER Medical AG
3. Prairie Education & Research Cooperative Joins MedNet Solutions iMedNet CRO Partner Program
4. Global pharmaceutical industry calls for broad-based cooperation to fight online sales of counterfeit medicines around the world
5. CooperVision Renews Its Support of U.S. Military Personnel
6. Herb Baer Appointed President of Polar USA
7. New Executive Vice President Commercial Appointed
8. Israel Makov Appointed Chairman of Sun Pharma Board
9. Dr. Paul Karila Appointed Head of Discovery Services at Cellectricon AB
10. Neal K. Long appointed as Chief Executive Officer at Cardiac Science
11. Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
Post Your Comments:
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... transport experience for the millions of people who require these medical transport services ... industry through the use of technology. Now, SmartEMS has put forth an industry-changing ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):